Ionis Pharmaceuticals has received FDA approval to expand Tryngolza (olezarsen) to a broader hypertriglyceridemia label, increasing the therapy’s commercial scope beyond an earlier rare classification. The approval adds opportunities in the severe hypertriglyceridemia segment and supports Ionis’ strategy of building out internal development and commercialization rather than relying on partners. Ionis previously secured strong phase III data, which set up a larger indication that also carried priority review and breakthrough therapy designations. The label expansion is expected to improve uptake by aligning treatment eligibility with more prevalent patient categories at risk for complications such as acute pancreatitis. For stakeholders, the move also intensifies competition in cardiometabolic risk management where antisense and other targeted modalities compete on dosing convenience and evidence strength.